Using CYP2D6 genotype to understand paroxetine-pimozide pharmacokinetics in man

被引：0

作者：

Foot, Elizabeth ^{[1
]}

Briley, Linda ^{[1
]}

McCarthy, Linda ^{[1
]}

Moate, Rachel ^{[1
]}

Reck, Brian ^{[1
]}

Muir, Keith ^{[1
]}

Stapleton, Carole ^{[1
]}

Cox, Charles ^{[1
]}

Dow, David ^{[1
]}

Mehta, Nalini ^{[1
]}

Latham, Ian ^{[1
]}

Goodgame, Neil ^{[1
]}

Vousden, Marika ^{[1
]}

Nucci, Gianluca ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Greenford, Middx, England

来源：

AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS | 2006年 / 141B卷 / 07期

关键词：

D O I：

暂无

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

引用

页码：786 / 786

页数：1

共 50 条

[1] EFFECT OF PAROXETINE ON THE PHARMACOKINETICS OF ATOMOXETINE IN DIFFERENT CYP2D6 GENOTYPE
Kim, S. H.
Byeon, J. Y.
Kim, Y. H.
Lee, H. J.
Lee, Y.
Lee, Y. J.
Kim, D. H.
Lim, H. J.
Lee, S. Y.
CLINICAL THERAPEUTICS, 2015, 37 (08) : E60 - E60
[2] Pharmacokinetics of atomoxetine after administration of paroxetine in relation to CYP2D6 genotype status
Kim, Dong-Hyun
Lim, Hye-Jin
Byeon, Ji-Yeong
Kim, Young-Hoon
Kim, Se-Hyung
PHARMACOTHERAPY, 2015, 35 (11): : E316 - E317
[3] Pharmacokinetics of paroxetine and genotype of CYP2D6 polymorphisms in the Japanese patients with dose escalation
Okazaki, N
Yamauchi, A
Nagai, H
Nishimura, R
Kataoka, Y
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 278P - 278P
[4] Impact of CYP2D6 Genotype on Paroxetine Serum Concentration
Hole, Kristine
Haslemo, Tore
Molden, Espen
THERAPEUTIC DRUG MONITORING, 2023, 45 (05) : 683 - 688
[5] CYP2D6 genotype and paroxetine pharmacokinetics in the elderly: A population pharmacokinetics analysis in depressed geriatric subjects.
Feng, Y
Pollock, BG
Ferrell, RE
Kimak, MA
Reynolds, C
Bies, RR
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P9 - P9
[6] Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
Belle, DJ
Ernest, CS
Sauer, JM
Smith, BR
Thomasson, HR
Witcher, JW
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11): : 1219 - 1227
[7] Effect of the CYP2D6*10 Genotype on Tolterodine Pharmacokinetics
Oishi, Masayo
Chiba, Koji
Malhotra, Bimal
Suwa, Toshio
DRUG METABOLISM AND DISPOSITION, 2010, 38 (09) : 1456 - 1463
[8] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
Kiss, Adam Ferenc
Toth, Katalin
Juhasz, Cintia
Temesvari, Manna
Paulik, Jozsef
Hirka, Gabor
Monostory, Katalin
MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
[9] CYP2D6 genotype and risperidone pharmacokinetics, pharmacodynamics and side effects
Novalbos, J.
Lopez-Rodriguez, R.
Roman, M.
PHARMACOGENOMICS, 2011, 12 (03) : 312 - 312
[10] Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype
Molden, E
Johansen, PW
Boe, GH
Bergan, S
Christensen, H
Rugstad, HE
Rootwelt, H
Reubsaet, L
Lehne, G
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (03) : 333 - 342

← 1 2 3 4 5 →